Navigation Links
Bradmer provides clinical trial update and announces evaluation of strategic alternatives
Date:2/17/2009

are evaluating strategic options related to the Bradmer assets and resources. While the cash on hand is not enough to finish the clinical trial, it is substantial enough to warrant careful consideration of proper deployment. It is envisioned that this strategic evaluation process will be reviewed by the Directors in March and recommendations will be forthcoming.

About Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common and most advanced form of brain cancer with approximately 30,000 new cases diagnosed each year in the world's seven largest healthcare markets. Unlike many other solid tumors, GBM tumors do not metastasize, but cause symptoms and often death through invasion of nearby tissues and impairment of brain function. The current standard of care, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), extended average overall patient survival from 53 to 64 weeks.

About Neuradiab

Neuradiab is a monoclonal antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab delivers tumor-killing radiation specifically to residual brain tumor cells after surgery, with minimal impact on normal brain tissue. During the course of development at Duke University, over US$60 million in research grants and related support has produced a series of Phase I and Phase II clinical trials on Neuradiab and other closely related technologies. Approximately 200 brain cancer patients, including over 160 with GBM, have been treated with the Neuradiab therapy regimen, and survival benefits have significantly exceeded historical controls in each completed trial. Neuradiab has been formerly referred to in literature as 131-I anti-tenascin monoclonal antibody 81c6.

GBM tumors typically have infiltrating edges that are very difficult to completely remove with surgery. The Ne
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
2. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
3. Bradmer announces 2008 third quarter operational and financial results
4. Bradmer to present at Rodman & Renshaw Healthcare Conference
5. Bradmer receives FDA approval to proceed with Phase III clinical trial
6. Bradmer announces 2008 first quarter operational and financial results
7. Bradmer announces new additions to management team
8. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
11. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an ... while raising money for breast cancer research. Pelican Water ... in the effort to find a cure. ... of having access to clean, healthy water. Research has ... certain forms of cancer. , The Problem of ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Generic drug ... retail generics increasing in price in the last 12 ... Inc.’s (AIS) Drug Benefit News (DBN) interviewed a plan ... means for pharmacies and health plans. , “When ... rising generic acquisition costs, these cost increases squeeze pharmacies’ ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3
... use of limited supplies of flu vaccine, according to research ... suggests that, used to support other control measures, this could ... swine flu. As the World Health Organization declares a ... to control the spread of the disease. These measures include ...
... , WEYMOUTH, Mass., June 17 Registration is underway for ... of Weymouth. Sessions begin on Monday, July 6 at ... , THE CPAP SUCCESS GROUP is designed to help struggling ... learn how to use CPAP more easily and effectively by learning ...
... hormone formulations provide significant pharmacological responses , , DALLAS, ... (OTC Bulletin Board: ACCP) ... two biopharmaceutical companies for its Cobalamin(TM) Oral Drug ... both companies plan to evaluate Access, Oral Insulin ...
... Lower doses safe and effective after heart attack and stroke ... pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack ... or suffer from unstable angina, a new trial shows. , ... involved in blood clotting. In earlier studies, the drug was ...
... Recognizes Entrepreneurial Excellence in Health and Life Sciences Category , ... -- Accuray Incorporated (Nasdaq: ARAY ), a ... Euan Thomson, Ph.D., the company,s president and CEO, received the ... the Health and Life Sciences category in Northern California. ...
... Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) ... agreement with Handok Pharmaceuticals Co., Ltd. ("Handok"), the ... under which Echo granted Handok rights to develop, ... ("Symphony") for painless, needle-free, transdermal, continuous glucose monitoring ...
Cached Medicine News:Health News:Vaccinating children may be effective at helping control spread of influenza, experts say 2Health News:Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth 2Health News:Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations 2Health News:Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations 3Health News:New Anticoagulant Pill Works Well in Trial 2Health News:New Anticoagulant Pill Works Well in Trial 3Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 4
(Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the Asia ... China , India , ... rate through 2023. Dental implant procedure volumes will grow as physicians ... Other key findings from Decision Resources Group,s coverage of ... , Dental implant penetration: Penetration of dental implants among ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , PHILADELPHIA, ... Dr. Michael J. McKelvey, the Company,s President and CEO, and Keith ... present at the 21st Annual Piper Jaffray Health Care Conference at ... New York. , Interested parties may access the presentation by visiting ...
... , , WEST PALM BEACH, Fla., ... Americans, especially the 27 million living with untreated hearing loss ... Cindy Beyer. , Dr. Beyer, senior vice president of HearUSA (Amex: ... hearing aids companies, said studies have linked hearing loss to ...
Cached Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3
... kit features a patented Per-fit™ flexible PVC ... a low-profile cuff specifically designed to reduce ... the patients anatomy. The kit s unique ... tube snugly, allowing for an easier transition ...
... Self-contained kits provide convenience and cost ... tracheostomy care trays offer a variety of ... and management of the tracheostomized patient. , ... trays, and trays with disposable inner cannula ...
Disposable tracheostomy care tray....
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
Medicine Products: